The Vanguard Group, Inc. recently announced the acquisition of new stake in PetMed Express Inc. (NASDAQ:PETS). The institutional investor has increased its shareholding in the Healthcare company by 7.39% to 1.48 million shares with purchase of 0.1 million shares. This fresh investment now brings its stake to 7.01% valued currently at $26.14 million. In addition, Charles Schwab Investment Managem raised its holdings by 50518.0 to 0.57 million shares. And Dimensional Fund Advisors LP has lifted its position by 0.68% or 3820.0 shares – to 0.57 million shares.
With over 0.24 million PetMed Express Inc. (PETS) shares trading Friday and a closing price of $19.13 on the day, the dollar volume was approximately $4.62 million. The shares have shown a negative half year performance of -12.61% and its price on 01/13/23 lost nearly -1.19%. Currently, there are 20.26M common shares owned by the public and among those 20.17M shares have been available to trade.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 37,500 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in PetMed Express Inc. are iShares Core S&P Small Cap ETF, Vanguard Total Stock Market Index, and Global X SuperDividend US ETF. iShares Core S&P Small Cap ETF owns 1.56 million shares of the company’s stock, all valued at over $27.68 million. The company sold 1184.0 shares recently to bring their total holdings to about 7.42% of the shares outstanding. Global X SuperDividend US ETF sold 936.0 shares to bring its total holdings to over 0.57 million shares at a value of $10.03 million. Global X SuperDividend US ETF now owns shares totaling to 2.69% of the shares outstanding.
Shares of PetMed Express Inc. (NASDAQ: PETS) opened at $19.24, down -$0.12 from a prior closing price of $19.36. However, the script later moved the day high at 19.58, down -1.19%. The company’s stock has a 5-day price change of 3.29% and -6.55% over the past three months. PETS shares are trading 8.08% year to date (YTD), with the 12-month market performance down to -22.74% lower. It has a 12-month low price of $17.08 and touched a high of $29.53 over the same period. PETS has an average intraday trading volume of 323.37K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.45%, -1.08%, and -9.49% respectively.
Institutional ownership of PetMed Express Inc. (NASDAQ: PETS) shares accounts for 80.50% of the company’s 20.26M shares outstanding. Mutual fund holders own 29.24%, while other institutional holders and individual stakeholders account for 49.41% and 26.71% respectively.
It has a market capitalization of $408.04M and a beta (3y monthly) value of 0.60. The stock’s trailing 12-month PE ratio is 24.81, while the earnings-per-share (ttm) stands at $0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.73% over the week and 3.25% over the month.
Analysts forecast that PetMed Express Inc. (PETS) will achieve an EPS of $0.25 for the current quarter, $0.23 for the next quarter and $1.06 for 2024. The lowest estimate earnings-per-share for the quarter is $0.22 while analysts give the company a high EPS estimate of $0.3. Comparatively, EPS for the current quarter was $0.31 a year ago. Earnings per share for the fiscal year are expected to decrease by -31.90%, and 30.25% over the next financial year. EPS should grow at an annualized rate of -0.02% over the next five years, compared to -2.40% over the past 5-year period.
Looking at the support for the PETS, a number of firms have released research notes about the stock. Sidoti stated their Buy rating for the stock in a research note on January 20, 2022, with the firm’s price target at $32. Morgan Stanley coverage for the PetMed Express Inc. (PETS) stock in a research note released on November 18, 2021 offered a Underweight rating with a price target of $25. Jefferies was of a view on October 01, 2021 that the stock is Hold, while Credit Suisse gave the stock Underperform rating on August 05, 2021, issuing a price target of $22. Sidoti on their part issued Neutral rating on June 03, 2021.